NYSE$IQV

IQVIA Holdings Inc. · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

IQVIA's Q4 2023 performance showed revenue growth and increased GAAP net income, driven by strong clinical demand in R&DS, while issuing full-year 2024 guidance.

IQVIA reported a 3.5% increase in revenue for Q4 2023, reaching $3,868 million. GAAP Net Income increased significantly to $469 million, and GAAP Diluted Earnings per Share rose to $2.54. The company issued full-year 2024 guidance, projecting revenue between $15,400 million and $15,650 million.

  • Q4 revenue reached $3,868 million, a 3.5% increase year-over-year.
  • GAAP Net Income for Q4 was $469 million, up 106.6% year-over-year.
  • R&D Solutions quarterly bookings exceeded $2.8 billion with a book-to-bill ratio of 1.31x.
  • Full-year 2024 revenue is projected to be between $15,400 million and $15,650 million.

Headline financials

Total Revenue

$3.87B

Previous: $3.74B+3.5%
EPS (adj)

$2.84

Previous: $2.78+2.2%
R&D Solutions contracted backlog

$29.7B

Previous: $27.2B+9.2%
Capital Expenditures

-$179M

No prior period
Net Income

$469M

Previous: $227M+106.6%
Operating Income

$501M

Previous: $379M+32.2%
Gross Profit

$1.12B

Previous: $1.33B-16.3%
Stock-Based Comp

$45M

Previous: $58M-22.4%

Revenue & EPS history

IQVIA · Revenue · Quarterly

$3.87B

Q4 2023+3.5%vs Q4 2022
Beat estimate in 12 of 15 quarters(80%)
ActualEstimate

Revenue by segment

IQVIA · $3.74B total across 3 segments · Q3 2023

  • Research & Development Solutions
    $2.12B+7.2%
  • Technology & Analytics Solutions
    $1.43B+2.2%
  • Contract Sales & Medical Solutions
    $183M+0.0%

Forward guidance

For the full year 2024, the company expects revenue to be between $15,400 million and $15,650 million, Adjusted EBITDA to be between $3,700 million and $3,800 million, and Adjusted Diluted Earnings per Share to be between $10.95 and $11.25.

Tailwinds

  • Revenue guidance assumes approximately $300 million of COVID-related revenue step down.
  • Revenue guidance includes about 50 basis points of headwind from foreign exchange.
  • Revenue guidance includes about 100 basis points of contribution from acquisitions.
  • Adjusted EBITDA is expected to be between $3,700 million and $3,800 million.
  • Adjusted Diluted Earnings per Share is expected to be between $10.95 and $11.25.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

+1.4%

Avg return

Earnings day

+1.6%

Avg return

5 days after

+1.9%

Avg return

30 days after

65%

37 / 57 earnings

Positive

+12.5%

Q2 2018

Best reaction

-10.7%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+7.7%+10.9%+13.9%
Q4 2025-10.7%-9.9%-13.8%
Q3 2025+0.3%-0.4%+6.6%
Q2 2025-0.4%+1.1%-1.6%
Q1 2025-4.0%-2.2%-3.2%
Q4 2024+2.2%-2.2%-6.7%
Q3 2024-3.2%-1.5%-7.0%
Q2 2024+6.3%+6.7%+10.0%
Q1 2024-4.1%-1.6%-5.9%
Q4 2023+12.2%+10.8%+17.4%
Q3 2023+5.3%+9.7%+20.0%
Q2 2023-2.1%-3.1%-0.5%
Q1 2023-0.9%-2.3%+5.0%
Q4 2022+0.8%-1.4%-14.4%
Q3 2022+1.4%+6.1%+11.3%
Q2 2022+0.5%-0.4%+8.3%
Q1 2022+6.1%+5.0%+6.7%
Q4 2021-3.2%-4.8%-6.9%
Q3 2021+2.1%+1.8%+6.6%
Q2 2021-0.8%+0.2%+4.5%
Q1 2021+6.1%+7.0%+9.1%
Q4 2020+4.9%+4.8%+1.6%
Q3 2020+3.2%+2.1%+3.4%
Q2 2020+2.9%+3.4%+0.4%
Q1 2020+8.5%+3.5%+10.9%
Q4 2019+2.5%+1.6%-26.6%
Q3 2019-3.8%-2.4%-2.7%
Q2 2019+2.1%+1.6%-2.3%
Q1 2019-2.0%-0.1%-2.2%
Q4 2018+7.6%+7.3%+7.4%
Q3 2018-3.5%-5.3%-8.4%
Q2 2018+12.5%+8.2%+11.7%
Q1 2018-0.7%+0.2%+2.6%
Q4 2017+1.5%+1.7%+5.6%
Q3 2017+6.1%+6.5%+2.7%
Q2 2017-1.3%-1.0%+4.4%
Q1 2017-3.7%-2.0%+3.0%
Q4 2016-2.7%-4.1%+0.5%
Q3 2016+0.8%+4.1%+3.3%
Q2 2016+3.3%+4.2%+0.3%
Q1 2016-5.9%
Q4 2015+3.6%
Q3 2015-6.2%
Q2 2015+2.6%
Q1 2015-4.9%
Q4 2014+4.3%
Q3 2014+0.9%
Q2 2014-3.1%
Q1 2014+0.4%
Q4 2011+7.5%
Q4 2013+7.5%
Q3 2012+0.1%
Q3 2013+0.1%
Q2 2012+0.8%
Q2 2013+0.8%
Q1 2012+5.0%
Q4 2012+5.0%
Q1 2013

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro